The alarming rate of obesity and weight gain in industrialized nations is one of the most concerning health issues plaguing developed countries today. Scientists might have just come much closer to finally ending this epidemic by preventing mice from gaining weight even with a steady diet of high-fat food. Could these findings lead to effortless weight loss?
Published on eLife, the study described how scientists from Washington University School of Medicine basically activated certain pathways in fat cells, which essentially allowed the mice to go on a high-fat diet without becoming obese. This could lead to some huge leaps in treating all the other diseases that are associated with weight gain, including type-2 diabetes.
“Here by inducing expression of constitutively active Smoothened (SmoM2) or Gli2 (ΔNGli2) in the adipocyte lineage of postnatal mice, we show that targeted activation of Hh signaling suppresses high-fat-diet-induced obesity and improves whole-body glucose tolerance and insulin sensitivity,” the study reads.
As senior investigator Fanxin Long, Ph.D. put it, these findings could lead to new ways to treat the growing obesity epidemic afflicting populations even in developing countries. It also makes preventing weight gain easier because it targets the root cause of the issue.
"This could lead us to a new therapeutic target for treating obesity," Long said. "What's particularly important is that the animals in our study ate a high-fat diet but didn't gain weight, and in people, too much fat in the diet is a common cause of obesity."
On that note, translating the results of this study to apply to humans might not be that easy, MedicalXpress reports. The test subjects and people don’t exactly have the same metabolism and the methods used to activate the pathways in fat cells to stop them from growing might cause unknown side-effects. It might even cause cancer if the application is not done properly.


Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Tabletop particle accelerator could transform medicine and materials science
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



